Shiri S, Shibuya M, Kawai A, Tamiya S, Munakata L, Omata D, Suzuki R, Aoshi T, Yoshioka Y. Lipid Nanoparticles Potentiate CpG-oligodeoxynucleotide-based Vaccine for Influenza Virus. Front Immunol. 2020 Jan 9;10:3018.
Shibuya M, Aoshi T, Kuroda E, Yoshioka Y. Murine cross-reactive non-neutralizing polyclonal IgG1 antibodies induced by influenza vaccine inhibit the cross-protective effect of IgG2 against heterologous virus in mice. J Virol. 2020 Jun 1;94(12):e00323-20.
Tamiya S, Yoshikawa E, Ogura O, Kuroda E, Suzuki K, Yoshioka Y. Vaccination using inactivated Mycoplasma pneumoniae induces detrimental infiltration of neutrophils after subsequent infection in mice. Vaccine. 2020 Jul 6;38(32):4979-4987.
Kawai A, Yamamoto Y, Yoshioka Y. Vaccine effect of recombinant single-chain hemagglutinin protein as an antigen. Heliyon. 2020 Jun 27;6(6):e04301.
Shiri S, Kawai A, Shibuya M, Munakata L, Omata D, Suzuki R, Yoshioka Y. Lipid Nanoparticle Acts as a Potential Adjuvant for Influenza Split Vaccine without Inducing Inflammatory Responses. Vaccines (Basel). 2020 Aug 3;8(3):E433.
ウイルスワクチングループ
Kanai Y, Onishi M, Kawagishi T, Pannacha P, Nurdin JA, Nouda R, Yamasaki M, Lusiany T, Khamrin P, Okitsu S, Hayakawa S, Ebina H, Ushijima H, Kobayashi T. Reverse genetics approach for developing rotavirus vaccine candidates carrying VP4 and VP7 genes cloned from clinical isolates of human rotavirus. J Virol. 2020 Dec 22; 95(2):e01374-20.
